ALAlphabet Inc.

Institutional investor · Portfolio as of Q2 2023

SEC EDGAR SourceSEC Filings

Top Holdings47 positions

Checking export access…
Activity:
Stock
Shares
Value
Weight
Avg Buy
Est. P&L
Held
Conviction

UIPATH INC

14.1M$233.1M12.5%$12.71+31.08%
3 qtrssince 2022-Q4
Unchanged
0
VERVVERVDelisted

VERVE THERAPEUTICS INC

10.5M$197.8M10.6%
3 qtrssince 2022-Q4
Unchanged
0

OSCAR HEALTH INC - CLASS A

24M$193.8M10.4%$2.46+234.15%
3 qtrssince 2022-Q4
Unchanged
0

CROWDSTRIKE HOLDINGS INC - A

1.3M$188.5M10.1%$120.06+19.93%
3 qtrssince 2022-Q4
Increased
66

PRIME MEDICINE INC

11.9M$173.8M9.3%$18.58-20.08%
3 qtrssince 2022-Q4
Decreased
0

DEXCOM INC

1.2M$155.9M8.4%$113.24+12.98%
3 qtrssince 2022-Q4
Decreased
0

GITLAB INC

2.6M$135.3M7.3%$43.53+13.71%
3 qtrssince 2022-Q4
Increased
78

PLANET LABS PBC

31.9M$102.9M5.5%$4.35-29.20%
3 qtrssince 2022-Q4
Unchanged
0

SNOWFLAKE INC-CLASS A

535,604$94.3M5.1%$143.54+22.45%
3 qtrssince 2022-Q4
Unchanged
0
EQRXEQRXDelisted

EQRx Inc.

47.7M$88.7M4.8%
3 qtrssince 2022-Q4
Unchanged
0

FRESHWORKS INC

4M$70.9M3.8%$14.71+19.65%
3 qtrssince 2022-Q4
Unchanged
0

LYFT INC-A

3.7M$35.5M1.9%$11.02+58.62%
3 qtrssince 2022-Q4
Unchanged
0
BHILBHILDelisted

Benson Hill Inc.

15.4M$20M1.1%
3 qtrssince 2022-Q4
Unchanged
0

RELAY THERAPEUTICS INC

1.6M$19.7M1.1%$14.94-14.32%
3 qtrssince 2022-Q4
Unchanged
0
DMDMDelisted

Desktop Metal Inc.

11M$19.6M1.1%

LYELL IMMUNOPHARMA INC

5.9M$18.7M1.0%

SANA BIOTECHNOLOGY INC

2.8M$16.8M0.9%$3.95+49.37%
3 qtrssince 2022-Q4
Unchanged
0

BEAM THERAPEUTICS INC

321,604$10.3M0.6%$39.11-18.67%
3 qtrssince 2022-Q4
Unchanged
0
RAPTRAPTDelisted

RAPT Therapeutics Inc.

540,270$10.1M0.5%

MONTE ROSA THERAPEUTICS INC

1.5M$10M0.5%$7.61-11.43%
3 qtrssince 2022-Q4
Unchanged
0
$1.9B
AUM
47
Positions
Q2 2023
Filing
Rating · 3.0
Quarterly Portfolio Change
+5%Q1'23$1.8B+3%Q2'23$1.9B
Activity profile
$ moved · Q2'23
New0%Increased39%Decreased25%Exited36%
Composition
Equity vs derivatives
Equity100%Puts0%Calls0%
Holding period
Avg 2.6 quarters
<1Q0%1-4Q91%1-2Y0%2Y+9%

Alphabet Inc. manages $1.9B across 47 positions as of Q2 2023. Top holdings: PATH (12.5%), VERV (10.6%), OSCR (10.4%). Fund DNA: Concentrated Value. HoldingsIntel Rating: 3/5.0.

Q2 2023 Summary

Exited 2, increased 2, trimmed 4. Top move: GTLB (INCREASED, conviction 78). Portfolio: $1.9B across 47 positions.

Top holdings by portfolio weight

Total AUM$2B
PATH12.53%
VERV10.63%
OSCR10.41%
CRWD10.13%
PRME9.34%
DXCM8.37%
GTLB7.27%
PL5.53%
SNOW5.06%
EQRX4.76%
Other3.81%

Portfolio allocation by GICS sector

Sectors5
Technology40.77%
Healthcare35.27%
Unknown18.07%
Industrials5.53%
Financial Services0.36%

Behavioral investing profile

Checking access…
Concentrated Value- primarily Technology, Healthcare, Unknown
Compare DNA across all funds
7-dimension quality assessment
Solid(3.0 / 5.0)
Track RecordNo data
Conviction37
Concentration100
Checking access…

Position Outcomes

Best and worst performing positions by estimated return

Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.

Similar Funds

Funds with similar investing DNA

Accumulation Streaks

Positions with 2+ consecutive quarters of increases - persistent directional conviction.

No active accumulation streaks detected for this filer.

Streaks require 2+ consecutive quarters of increased positions in the most recent period.

Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used